Biotech醫藥股

http://www.biopharmcatalyst.com/fda-calendar/
FDA calendar

http://bbs.wenxuecity.com/finance/3094583.html
炒Biotech醫藥股

ARNA 治療肥胖症的藥物, 已獲得SFDA批準.

VVUS

KERX 治療腎病的藥物臨床試驗收報告,結果好.

ARIA 它有3個有希望的在研藥物

.

http://bbs.wenxuecity.com/finance/3095034.html
小藥股的比較賺錢的抄法：

http://bbs.wenxuecity.com/finance/3106965.html
GILD

http://bbs.wenxuecity.com/finance/3104396.html
ACAD

http://bbs.wenxuecity.com/finance/3231640.html
從單克隆抗體生化藥股想開去，，，

ZT

Regeneron Pharmaceuticals (NASDAQ: REGN) is flying higher on Friday by 3.5% – it has produced gains of 10% this week – after Lazard Capital upgraded shares from Neutral to Buy. Apparently, Lazard likes the upside in its eye drug Eylea; this product is responsible for Regeneron’s 80% growth.

 

Just to be clear, when Regeneron was trading below $220 I was writing, tweeting, and screaming to buy the stock. But now, at $260, I think it’s getting a bit expensive. Look, I love the long-term potential of this company; I think that once its large pipeline develops that it will trade considerably higher; but at 15 times sales, I think there are better short-term opportunities elsewhere. But once the company’s rheumatoid arthritis drug Sarlimab is approved, my outlook is likely to change.

http://investorplace.com/2013/08/8-biotechnology-stocks-to-buy-now-insy-aria-pran/

 http://bbs.wenxuecity.com/finance/3291498.html
說兩句：MNKD　(摸你褲底）

http://bbs.wenxuecity.com/finance/3332078.html
Earnings after the bell: $AVNR $DDC $HRB $IRET $MIND $NCS $PPHM

http://bbs.wenxuecity.com/finance/3299409.html
從Aria, VVUS說說藥股新藥的怪圈

http://bbs.wenxuecity.com/finance/3329192.html
2014 FDA Drug Approval Decision Calendar

http://bbs.wenxuecity.com/finance/3340605.html
年末總結MNKD, ARIA

http://bbs.wenxuecity.com/finance/3343326.html
可能翻倍的三隻生物技術股2014年

http://bbs.wenxuecity.com/finance/3351815.html
談談生藥股

http://bbs.wenxuecity.com/finance/3352931.html
戲說ＡＭＳＮ的風險與欺詐（１）

http://bbs.wenxuecity.com/finance/3359643.html
再來看看“高價”生藥股是怎麽瀉的

http://bbs.wenxuecity.com/finance/3359550.html
看看“高價”生藥股是怎麽飆的。。。